Johnson and Johnson

29 oct. 2026, 23:01 UTC

Johnson & Johnson shares advanced during after-market hours, reflecting a broader upward movement in the Pharmaceuticals sub-sector amid recent higher daily closes.

28 oct. 2026, 23:02 UTC

Johnson & Johnson shares advanced in after-market trading, supported by gains in the Pharmaceuticals sub-sector, and remain significantly above their 20-day moving average.

27 oct. 2026, 23:01 UTC

Johnson & Johnson shares are modestly lower in after-market trading, having shifted from a slight gain to a more significant loss today.

26 oct. 2026, 20:07 UTC

Johnson & Johnson reported positive clinical data at the European Society for Medical Oncology Congress 2026, showing strong response rates for its investigational drug JNJ-6143.

23 oct. 2026, 19:56 UTC

Johnson & Johnson is under investigation by Bronstein, Gewirtz & Grossman, LLC, after a significant decline in net earnings and disappointing MedTech sales.

22 oct. 2026, 23:51 UTC

Johnson & Johnson shares traded modestly lower during after-market hours on Thursday, breaking a recent trend of higher daily closes.

21 oct. 2026, 23:06 UTC

Johnson & Johnson shares advanced in after-market trading, reflecting a modest increase since Wednesday's close and currently positioned in the middle of its one-month range.

20 oct. 2026, 22:51 UTC

Johnson & Johnson's shares are trading modestly lower in after-market hours, amid broader weakness in the Pharmaceuticals sub-sector, reaching the day's lowest point.

19 oct. 2026, 20:07 UTC

Johnson & Johnson reported positive Phase 3 FUZION study results for TREMFYA, showing improved fistula remission in Crohn's disease patients over 48 weeks.

16 oct. 2026, 23:01 UTC

Johnson & Johnson shares are trading modestly lower in after-market hours, having reached their lowest cumulative return of the day.

15 oct. 2026, 23:06 UTC

Johnson & Johnson reported Q3 sales of $25.4 billion and raised its full-year sales growth guidance to approximately 7%, with shares flat in after-market hours.

14 oct. 2026, 23:41 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from a low shortly after the market closed and reaching a notable high by late in the session.

13 oct. 2026, 23:01 UTC

Johnson & Johnson shares advanced modestly in after-market trading, recovering from a low shortly after Tuesday's close, but remain below their 20-day moving average.

12 oct. 2026, 20:07 UTC

Q3 earnings announcement on October 13; EPS forecast at $2.52.

9 oct. 2026, 23:50 UTC

Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEADa study for ICOTYDE® in treating moderate-to-severe plaque psoriasis.

8 oct. 2026, 23:05 UTC

Johnson & Johnson shares declined in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

7 oct. 2026, 20:01 UTC

Guggenheim reiterated its Buy rating on Johnson & Johnson with a $287 price target as the stock advances, having gained momentum since Tuesday's close.

6 oct. 2026, 20:07 UTC

RBC Capital maintained its Outperform rating on Johnson & Johnson and raised its price target to $290, contributing to a modest increase in shares today.

5 oct. 2026, 19:52 UTC

Johnson & Johnson shares fell sharply despite Citi raising its price target to $303 ahead of next week's earnings report, continuing a trend of lower performance.

2 oct. 2026, 20:07 UTC

Johnson & Johnson shares declined as the company presented positive data from its ICONIC-TOTAL study, showing 70% of patients achieved clear skin at Week 112.

1 oct. 2026, 23:05 UTC

Johnson & Johnson is trading slightly higher in after-market hours, recovering from three consecutive lower daily closes, though still below its 20-day moving average.

30 sept. 2026, 23:01 UTC

Johnson & Johnson's shares rose in after-market trading, buoyed by stronger-than-expected GDP growth of 2.2% for Q2, revised from 1.5%.

29 sept. 2026, 20:01 UTC

Johnson & Johnson's shares fell sharply as Bank of America Securities projects Q3 earnings below consensus, with a price target raised to $278.

28 sept. 2026, 20:07 UTC

Johnson & Johnson shares are higher following positive long-term efficacy results for its CAR T therapy, Carvykti, presented at the International Myeloma Society congress.

26 sept. 2026, 00:01 UTC

Johnson & Johnson's TREMFYA® met endpoints in the Phase 4 STAR study, but the stock is trading lower in after-market hours amid routine fluctuations.

25 sept. 2026, 20:07 UTC

Johnson & Johnson's stock rose after positive Phase 4 STAR study results for Tremfya and encouraging long-term data for CARVYKTI in multiple myeloma patients.

24 sept. 2026, 23:01 UTC

Johnson & Johnson's shares are advancing in after-market trading, holding a roughly flat position since Thursday's close amid limited fluctuations.

23 sept. 2026, 23:05 UTC

Johnson & Johnson is experiencing a slight decline in after-market trading, reflecting a cumulative return near the lower end of its one-month trading range.

22 sept. 2026, 20:07 UTC

Johnson & Johnson shares fell following a slight decline from Monday's close, despite bullish social media sentiment and positive Phase 3 study results for CAPLYTA®.

21 sept. 2026, 20:06 UTC

Johnson & Johnson's stock is declining today despite receiving EU approval for ICOTYDE, a new treatment for plaque psoriasis, and positive Phase 3 results for Caplyta.